

PATIENT INFORMATION			
Name:	Date of Birth:	<input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:	City:	State:	Zip:
Phone:	Alt Phone:	Email:	
SS #:	Primary Language:	Emergency Contact:	

PRESCRIBER INFORMATION			
Prescribing Practitioner:	NPI#:		
Supervising Physician:	NPI#:		
Address:	City:	State:	Zip:
Phone:	Fax:	Tax ID:	
			Office Contact:

PRESCRIPTION INFORMATION			
Needs by Date:	Ship to: <input type="checkbox"/> Patients home <input type="checkbox"/> Prescriber 1st order only <input type="checkbox"/> Prescriber all orders <input type="checkbox"/> Other		
Drug	Dose	Direction & Quantities	Refills
<input type="checkbox"/> Humira	<input type="checkbox"/> Psoriasis Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (1 Kit) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Qty: 2)	
<input type="checkbox"/> Humira CF	<input type="checkbox"/> HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 160 mg SQ on day 1, then 80 mg on day 15 (1 Kit) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Qty: 4)	
<input type="checkbox"/> Ilumya	<input type="checkbox"/> 100 mg Pre-filled syringe	<input type="checkbox"/> INITIAL: Inject 100 mg SC at week 0 and week 4 (Qty: 2) <input type="checkbox"/> MAINTENANCE: Inject 100 mg SC every 12 weeks (Qty: 1)	
<input type="checkbox"/> Otezla®	<input type="checkbox"/> 28 Day Starter Pack <input type="checkbox"/> Maintenance	<input type="checkbox"/> Take as directed per package instructions. (Qty: 55) <input type="checkbox"/> Take 30 mg PO twice daily (Qty: 60) <input type="checkbox"/> Take 30 mg PO once daily (Qty: 30). Renal Dosing Continuation of Therapy: <input type="checkbox"/> Yes <input type="checkbox"/> No	
<input type="checkbox"/> Siliq™	<input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 210 mg SC on weeks 0 and 1 (Qty: 2) <input type="checkbox"/> MAINTENANCE: Inject 210 mg SC every 2 weeks starting at week 2 (Qty: 2) <input type="checkbox"/> REMS	
<input type="checkbox"/> Skyrizi™	<input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Pen injector	<input type="checkbox"/> INITIAL: Inject 150 mg SC at week 0 and week 4 <input type="checkbox"/> MAINTENANCE: Inject 150 mg SC every 12 weeks thereafter	
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45 mg <100 kg <input type="checkbox"/> 90 mg >100kg <input type="checkbox"/> Vials 45 mg	<input type="checkbox"/> INITIAL: Inject SC on day 0 and day 28 (Qty: 2) <input type="checkbox"/> MAINTENANCE: Inject SC every 12 weeks (Qty: 1)	
<input type="checkbox"/> Taltz®	<input type="checkbox"/> 80 mg/ml autoinjector <input type="checkbox"/> 80 mg/ml Pre-filled syringe	<input type="checkbox"/> INITIAL: inject 160mg SC at week 0, then begin induction dose 2 weeks later. (Qty: 3) <input type="checkbox"/> INDUCTION DOSE: inject 80mg SC every two weeks (weeks 4 - 10). (Qty: 2 pens/syringes) <input type="checkbox"/> FINAL INDUCTION DOSE: inject 80mg SC at week 12. (Qty: 1 pen/syringe) <input type="checkbox"/> MAINTENANCE DOSE: inject 80 mg SC every 4 weeks (thereafter) (Qty: 1 pen/syringe)	
<input type="checkbox"/> Tremfya™	<input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> One - Press Injector	<input type="checkbox"/> INITIAL: Inject 100 mg SC on week 0 and week 4 (Qty: 1) (Refill: 1) <input type="checkbox"/> MAINTENANCE: Inject 100 mg SC every 8 weeks (Qty: 1)	

MEDICAL INFORMATION			
** PLEASE FAX COPY OF PRESCRIPTION MEDICATION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY **			
PREVIOUS THERAPIES:	<input type="checkbox"/> Cyclosporine	<input type="checkbox"/> Elidel	PHOTOTHERAPY
	<input type="checkbox"/> Methotrexate	<input type="checkbox"/> Eucrisa	<input type="checkbox"/> UVA /UVB
	<input type="checkbox"/> Soriatane	<input type="checkbox"/> Stelara	
	<input type="checkbox"/> Clobetasol	<input type="checkbox"/> Humira	<input type="checkbox"/> Other: _____
	<input type="checkbox"/> Hydrocortisone	<input type="checkbox"/> Enbrel	

Tried & Failed (Duration): _____

Contraindication: _____

L40.0 Psoriasis Vulgaris (Plaque Psoriasis) L40.9: Psoriasis, unspecified. L32.2 HS Date of Diagnosis: ___/___/___

Active TB is ruled out: Yes No Date: ___/___/___ Hep B ruled out/treated: Yes No Date: ___/___/___

Allergies: _____ Patient Height: _____ in/cm Weight: _____ kg/lbs

Additional Clinical Information: _____

AMERICAN ACADEMY OF DERMATOLOGY CONSENSUS STATEMENT ON PSORIASIS THERAPIES	
<input type="checkbox"/> Psoriasis is covering greater than 10% of body surface area	<input type="checkbox"/> Psoriasis is on palms, soles, head and neck, or genitalia
<input type="checkbox"/> Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints	
<input type="checkbox"/> Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships.	

INJECTION TRAINING	
<input type="checkbox"/> Patient has received pen and injection training	<input type="checkbox"/> Parkway Pharmacy to coordinate injection training

PRESCRIBING PRACTITIONER SIGNATURE	
<u>To Prescribing Practitioner:</u>	
designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescribing Practitioner:	Date

CONFIDENTIALITY NOTICE	
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.	
Faxed Prescriptions will only be accepted from a prescribing practitioner.	